Post-earnings recap
Reported
Thu, Nov 14, 2024
EPS actual
$-1.82
EPS est.
$-1.54
EPS surprise
-17.82%
1-day move
-1.39%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Ascendis Pharma reported a larger-than-expected loss per share for Q3-2024, which resulted in a 1.39% decline in stock price. The lack of revenue data and management commentary leaves investors with limited insight into the company's future performance. The negative EPS surprise may raise concerns about the company's financial health moving forward.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.82 | N/A | -17.82% |
| Revenue | N/A | N/A | N/A |
No transcript is on record, and the analysis is based on numerical results only.